Search research articles
Contact Us
Filters
Showing results (501-510 of 759) with videos related to
Page
of 76
Sort By:
Blood Cancer Journal
|
November 10, 2018
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
M Hasib Sidiqi, Mohammed A Aljama, Irbaz Bin Riaz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2013
Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation
Abhishek Singla, William J Hogan, Stephen M Ansell, et al.
Blood
|
June 25, 2014
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Wilson I Gonsalves, S Vincent Rajkumar, Ronald S Go, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology
|
May 3, 2012
Trends and outcomes of modern staging of solitary plasmacytoma of bone
Rahma Warsame, Morie A Gertz, Martha Q Lacy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
Irene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Haematologica
|
August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type
Eli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
American Journal of Hematology
|
April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis
Eli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma
Shaji Kumar, Betsy Knopf, Erik Asmus, et al.
Leukemia
|
November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
Alissa Visram, Celine Vachon, Linda B Baughn, et al.
Page
of 76
Search research articles
Search
Showing results (501-510 of 759) with videos related to
Sort By:
Page
of 76
Blood Cancer Journal
|
November 10, 2018
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
M Hasib Sidiqi, Mohammed A Aljama, Irbaz Bin Riaz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 11, 2013
Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation
Abhishek Singla, William J Hogan, Stephen M Ansell, et al.
Blood
|
June 25, 2014
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Wilson I Gonsalves, S Vincent Rajkumar, Ronald S Go, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
American Journal of Hematology
|
May 3, 2012
Trends and outcomes of modern staging of solitary plasmacytoma of bone
Rahma Warsame, Morie A Gertz, Martha Q Lacy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
Irene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Haematologica
|
August 2, 2016
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type
Eli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
American Journal of Hematology
|
April 11, 2025
The Impact of Melphalan Conditioning and CD34 <sup>+</sup> Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis
Eli Muchtar, Vaishali Sanchorawala, Hamza Hassan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma
Shaji Kumar, Betsy Knopf, Erik Asmus, et al.
Leukemia
|
November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
Alissa Visram, Celine Vachon, Linda B Baughn, et al.
Page
of 76